Drug Trial Radar · NCT05745207
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Feb 20, 2023
Primary completion
Jan 18, 2024
Study completion Jan 18, 2024
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Feb 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of E2086 following administration of a single oral doses in healthy adult and elderly participants.
Conditions
- Healthy Volunteers
Interventions
E2086Drug
E2086 tablets.
PlaceboDrug
E2086 matched placebo tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From Screening up to 10 days
- Number of Participants With Serious Adverse Events (SAEs)Time frame: From Screening up to 10 days
- Number of Participants With Clinically Significant Abnormal Laboratory ValuesTime frame: From Screening up to 10 days
- Number of Participants With Clinically Significant Abnormal Vital Signs ValuesTime frame: From Screening up to 10 days
- Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs) FindingsTime frame: From Screening up to 10 days
- Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-suicide Severity Rating Scale (C-SSRS)Time frame: From Screening up to 10 days
- Number of Participants With Clinically Significant Abnormal Physical Examination FindingsTime frame: From Screening up to 10 days
- Number of Participants With Clinically Significant Abnormal Neurological Examination FindingsTime frame: From Screening up to 10 days
- Number of Participants With Clinically Significant Abnormal Electroencephalogram (EEG) FindingsTime frame: Baseline, Days 1 and 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Worldwide Clinical Trials
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.